Compare WVE & DBRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WVE | DBRG |
|---|---|---|
| Founded | 2012 | 1991 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 2015 | N/A |
| Metric | WVE | DBRG |
|---|---|---|
| Price | $13.35 | $15.38 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 7 |
| Target Price | ★ $31.47 | $16.00 |
| AVG Volume (30 Days) | 2.2M | ★ 2.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 0.26% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,704,000.00 | N/A |
| Revenue This Year | N/A | $373.39 |
| Revenue Next Year | $119.93 | $8.23 |
| P/E Ratio | ★ N/A | $252.25 |
| Revenue Growth | ★ 149.43 | N/A |
| 52 Week Low | $5.28 | $6.41 |
| 52 Week High | $21.73 | $15.55 |
| Indicator | WVE | DBRG |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 54.80 |
| Support Level | $12.53 | $15.32 |
| Resistance Level | $14.56 | $15.47 |
| Average True Range (ATR) | 0.79 | 0.05 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 23.84 | 20.83 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.